An anti-Spike (SARS-CoV-2) antibody.
Emergency use authorization
Imdevimab is a fully human monoclonal antibody targeting and neutralizing SARS-CoV-2 Spike protein (Hansen et al., 2020).
On November 21, 2020, FDA issued an emergency use authorization for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. This includes those who are 65 years of age or older or who have certain chronic medical conditions.
|Link||Tested on||Impact factor||Notes||Publication date||DB entry date|
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
antibody in vitro mixed substance peptide RNA small molecule Spike protein
|Caco-2 cells; Vero cells; Sera of vaccinated individuals; (VSV) SARS-CoV-2 Spike-pseudotyped virus (WT, B.1.1.7, B.1.351, ant P.1 variants)||38.64||
Imdevimab displayed in vitro inhibition of SARS-CoV-2 Spike-pseudotyped virus infection for all tested emergent Spike variants (B.1.1.7, B.1.351, and P.1).
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
|Vero E6 cells||41.85 2019||
REGN10987+REGN10933 antibody cocktail
|ID||Title||Status||Phase||Start date||Completion date|
|NCT04852978||COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers||Recruiting||Phase 2||Apr/29/2021||Aug/30/2022|
|NCT04790786||UPMC OPTIMISE-C19 Trial, a COVID-19 Study||Recruiting||Phase 3||Mar/10/2021||Dec/01/2022|
|NCT04666441||COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection||Active, not recruiting||Phase 2||Dec/15/2020||Aug/13/2021|
|NCT04840459||Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting||Recruiting||Phase 2||Nov/20/2020||Jan/31/2022|
|NCT04519437||Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19||Active, not recruiting||Phase 1||Jul/26/2020||Oct/25/2021|
|NCT04452318||COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay||Active, not recruiting||Phase 3||Jul/13/2020||Sep/25/2021|
|NCT04425629||Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19||Recruiting||Phase 2|Phase 3||Jun/16/2020||Nov/26/2021|
|NCT04426695||Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19||Active, not recruiting||Phase 1|Phase 2||Jun/10/2020||Jun/04/2021|
|NCT04617535||Compassionate Use of REGN-COV2 for the Treatment of COVID-19||Available||Jan/01/1970||Jan/01/1970|